Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. Eidos seeks to treat this well-defined family of diseases at their collective source by stabilizing TTR.